文献速递冠心病血脂与心血管预防

冠状动脉钙化:从风险预测到治疗分配与临床试验

Coronary artery calcium: from risk prediction to treatment allocation and clinical trials.
PubMed 文献 · Heart · 2023-10-26

冠状动脉钙化(CAC)是冠状动脉粥样硬化负荷的直接测量指标,CAC水平越高,心血管疾病(CVD)事件风险越高,极高CAC者的CVD风险接近既往有CVD事件的稳定患者;CAC=0则与长期低CVD风险相关,即使在传统危险因素判定的高危人群中亦然。指南已将CAC用于他汀与非他汀类CVD预防治疗的分配,随机试验亦将CAC确立为识别最可能从药物治疗中获益的高危患者的工具。

要点

  • CAC是冠脉粥样硬化负荷的直接指标,水平越高CVD事件风险越高。
  • CAC=0与长期低CVD风险相关,可用于排除阻塞性冠心病。
  • CAC已用于指导他汀与非他汀类预防治疗的分配。

核心结论

  • CAC从风险预测工具扩展为CVD预防治疗分配与临床试验高危患者筛选的工具。

主要发现

  • CAC水平越高,CVD事件风险越高,极高CAC者的CVD风险接近既往有CVD事件的稳定患者。
  • CAC=0与长期低CVD风险相关,即使在传统危险因素判定的高危人群中亦然。
  • 动脉粥样硬化总负荷是比单纯关注冠状动脉狭窄更强的CVD危险因素。
  • CAC=0对排除阻塞性冠状动脉疾病有很高的阴性预测价值。
  • 人工智能使所有非门控胸部CT上的CAC自动判读成为可能。

关键数值与推荐

  • 指南基于CAC的CVD预防治疗分配作用已扩展至他汀与非他汀类药物。
  • CAC=0在低危有症状患者中用于排除阻塞性冠状动脉疾病的价值获证据支持。
  • CAC已在随机试验中确立为识别最可能从药物治疗获益的高危患者的工具。

临床怎么用

  • 可依据CAC水平分配他汀与非他汀类CVD预防治疗。
  • 可利用CAC=0的高阴性预测价值排除阻塞性冠状动脉疾病。
  • 可对非门控胸部CT常规评估CAC并借助人工智能自动判读。

局限性

  • 未来需纳入Agatston评分以外的粥样硬化测量以进一步优化CAC评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronary artery calcium (CAC) is a direct measure of an individual's coronary atherosclerotic burden. Higher levels of CAC are strongly associated with an increased risk of cardiovascular disease (CVD) events and individuals with very high CAC levels have a CVD risk similar to stable persons with a prior CVD event. Conversely, the absence of CAC (CAC=0) is associated with a low long-term risk of CVD, even among groups classified as high risk based on traditional risk factors. Accordingly, the guideline-based role of CAC in allocation of CVD prevention therapies has expanded to include both statin and non-statin medications. Beyond prevention therapies, it is now widely recognised that the total burden of atherosclerosis is a stronger risk factor for CVD than a sole focus on coronary stenosis. Furthermore, evidence is accruing to support expanding the value of CAC=0 among low-risk symptomatic patients given its very high negative predictive value for ruling out obstructive coronary artery disease. There is now an appreciation of the value of routine assessment of CAC on all non-gated chest CTs and with the advent of artificial intelligence, automated interpretation is now possible. Additionally, CAC is now firmly established in randomised trials as a tool to identify high-risk patients most likely to benefit from pharmacotherapies. Future studies incorporating measures of atherosclerosis beyond the Agatston score will lead to continued refinement of CAC scoring, further improvements in personalisation of CVD risk prediction and more individualised allocation of prevention therapies to the patients at highest CVD risk.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Whelton SP, Blaha MJ. Coronary artery calcium: from risk prediction to treatment allocation and clinical trials. Heart. 2023. PMID: 37130748. doi:10.1136/heartjnl-2022-321711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。